Advertisement

Topics

Recent Analysts' Ratings Changes for Gilead Sciences

06:50 EDT 29 Jul 2017 | Topix

They now have a $84.00 price target on the stock. According to Zacks, "Gilead reported better-than-expected results for the second quarter driven by positive trends in the non-HCV business and improved results from HCV business due to rapid uptake of Epclusa.

Original Article: Recent Analysts' Ratings Changes for Gilead Sciences

NEXT ARTICLE

More From BioPortfolio on "Recent Analysts' Ratings Changes for Gilead Sciences"

Quick Search
Advertisement